• 论坛首页
  • 我的丁香客
  • 精品栏目
    微话题
    微访谈
    病例挑战
  • 找人
    查找好友
    认证专家
    专家主页
    机构主页
    可能感兴趣
  • 随便看看
  • 更多
    丁香园
    丁香通
    丁香人才
    丁香会议
    丁香搜索
    丁香医生
    丁香无线
    丁香导航
    丁当铺
    文献求助
    医药数据库
    丁香诊所
    来问医生
登录 注册

科技动态

关注今日:10 | 主题:422173
论坛首页  >  医药生命科学动态跟踪   >  内分泌
  • 发帖
    每发1个新帖
    可以获得0.5个丁当奖励
  • 回帖

分享到:

  • 微信

    微信扫一扫

  • 微博
  • 丁香客
  • 复制网址

【medical-news】【资讯翻译】初步研究显示细胞因子抗体有助于治疗糖尿病

  • 只看楼主
  • 页码直达:
  • 直达末页
楼主 duguhuanmeng
duguhuanmeng
内分泌科
铁杆站友

  • 85
    积分
  • 64
    得票
  • 111
    丁当
  • 1楼
这个帖子发布于6年零259天前,其中的信息可能已发生改变或有所发展。
认领翻译的战友请跟帖注明“认领本文翻译,若48小时内未完成,请其他战友认领!
请根据自己的专业背景选择相应的资讯认领,经常认领而不能及时提供优质稿件者将被列入黑名单,取消认领资格,请大家注意!
新近参与本次活动的会员请查看:http://news.dxy.cn/bbs/topic/21537141 翻译时请把不确定的地方用红色字体标注,
寻找最近的翻译贴请查看:点击进入
翻译时请参照版规 http://news.dxy.cn/bbs/topic/8600034
翻译三天未加分找 http://news.dxy.cn/bbs/topic/7560523
举报和合并加分专贴 http://news.dxy.cn/bbs/topic/22202798
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分。
原文链接 http://www.medpagetoday.com/Endocrinology/Diabetes/38068


Antibody Tx for Diabetes 'Promising' in Early Study

By Michael Smith, North American Correspondent, MedPage Today
Published: March 26, 2013

An antibody against the cytokine interleukin-1 beta was safe, well tolerated, and had "modest" benefits in patients with type 2 diabetes, researchers reported.

The findings, from an industry-sponsored phase II study, suggest that blocking the activity of the cytokine "holds promise" as an adjuvant therapy for diabetes, according to Joanne Sloan-Lancaster, PhD, of Eli Lilly in Indianapolis, and colleagues.

But larger and longer studies will be needed to establish that promise as a therapeutic option, Sloan-Lancaster and colleagues cautioned online in Diabetes Care.

Research has suggested that higher than normal levels of acute-phase proteins, cytokines, and chemokines may play a role in the pathology of the disease, the researchers noted.

Among them, interleukin-1beta has been a prime suspect -- it has pro-inflammatory effects, blocks beta-cell function, and promotes beta-cell death.

For those reasons, Sloan-Lancaster and colleagues noted, it would make sense that blocking interleukin-1 beta could increase insulin production, improve insulin sensitivity, and slow disease progression.

To test the idea, they studied an investigational antibody against the cytokine -- LY2189102, or LY for short -- against placebo in a multicenter randomized, double-blind trial aimed at determining its efficacy, safety, and tolerability.

Between June 2009 and November 2010, they randomized 106 diabetes patients to get either subcutaneous placebo once a week for 12 weeks, or one of three doses of LY -- 0.6, 18, or 180 milligrams.

The primary endpoint was the change from baseline in average plasma glucose concentration, as measured by glycosylated hemoglobin (HbA1c), but the researchers also analyzed fasting glucose, postprandial glycemia, and inflammatory biomarkers, as well as safety and tolerability.

The primary endpoint was measured in the subgroup of patients -- 79 in all -- who received at least 11 doses of study drug or placebo. The researchers found that, compared with placebo:

  • The 0.6-milligram dose of LY was associated with 0.27% drop in HbA1c after 12 weeks.
  • The 18-milligram dose was associated with a 0.38% drop.
  • And the 180-milligram dose was associated with a 0.25% decline.


The effect was partly reversed by the end of follow-up, 12 weeks after the end of treatment, Sloan-Lancaster and colleagues reported.

Fasting glucose was reduced during treatment but also rebounded after the end of therapy. Also, postprandial glycemia was significantly reduced (P=0.02) at the end of dosing but there was no longer a significant effect by the end of 12 weeks of follow-up.

The researchers saw a significant (P<0.05) and rapid decline in high sensitivity C-reactive protein that was evident by week 4, reached an average decline of 77% at the end of therapy, and persisted until the end of follow-up.

Sloan-Lancaster and colleagues also saw apparent declines in interleukin-6 but they only reached significance for the 180-milligram group at weeks 4 and 12.

The antibody was well tolerated, with similar rates of treatment-emergent adverse events in both the placebo arm and the LY arms -- 74.1% and 77.2%, respectively.

The most common adverse events for all LY doses combined were headache, nasopharyngitis, arthralgia, and diarrhea. Five patients stopped treatment because of adverse events, but the only three serious such events were not judged to be related to the study drug.

Primary source: Diabetes Care
                     Source reference:
Sloan-Lancaster J, et al "Double-blind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1b antibody, in patients with type 2 diabetes" Diabetes Care 2013; DOI: 10.2337/dc12-1835.
  • 邀请讨论
  • 不知道邀请谁?试试他们

    换一换
2013-03-27 22:11 浏览 : 723 回复 : 6
  • 投票
  • 收藏 2
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
  • • 「胃复安」使用 12h 后患者死亡,这些雷区你都避开了吗?
axun_dxy
axun_dxy
科室保密
铁杆站友

  • 42
    积分
  • 1459
    得票
  • 642
    丁当
  • 2楼
认领本文翻译,若48小时内未完成,请其他战友认领!
2013-03-27 22:29
  • 投票
  • 收藏
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
  • • 筋膜炎如何彻底治愈
喜梅ximei
喜梅ximei
入门站友

  • 0
    积分
  • 0
    得票
  • 91
    丁当
  • 3楼
我要认领这篇文章,怎么认领呢?直接给版主发帖回复?翻译后怎么提交上去?
2013-03-29 09:28
  • 投票
  • 收藏
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
  • • 南京市儿童医院的危害远甚莆田系
楼主 duguhuanmeng
duguhuanmeng
内分泌科
铁杆站友

  • 85
    积分
  • 64
    得票
  • 111
    丁当
  • 4楼
喜梅ximei
我要认领这篇文章,怎么认领呢?直接给版主发帖回复?翻译后怎么提交上去?
这篇已经认领了。
可以参照其他已经翻译好的资讯的格式,认领、提交都是在帖子下面的回复里面。
2013-03-29 12:16
  • 投票
  • 收藏
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
  • • 2020第五届深圳国际电动牙刷产品展览会

关闭提示

需要2个丁当

丁香园旗下网站

  • 丁香园
  • 用药助手
  • 丁香通
  • 文献求助
  • 丁香人才
  • 丁香医生
  • 丁香导航
  • 丁香会议
  • 手机丁香园
  • 医药数据库

关于丁香园

  • 关于我们
  • 丁香园标志
  • 友情链接
  • 联系我们
  • 加盟丁香园
  • 版权声明
  • 资格证书

官方链接

  • 丁香志
  • 丁香园新浪微博
引用回复